Vaccine (DNA plasmid) · Immune activation, directed at HPV-6 E6 protein and HPV-6 E7 protein · developed by INOVIO PHARMACEUTICALS
INO-3106 is a DNA vaccine consisting of plasmids encoding HPV-6 E6 and E7 proteins, administered via intramuscular electroporation. It elicits cytotoxic T-lymphocyte responses against tumor cells expressing these viral proteins, resulting in tumor cell lysis. It is studied in aerodigestive precancerous lesions and malignancies associated with HPV-6 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02241369 | Phase 1 | Aerodigestive Precancerous Lesions and Malignancies | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Aerodigestive Precancerous Lesions and Malignancies
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →